Tags

Type your tag names separated by a space and hit enter

[Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension].
Arch Inst Cardiol Mex. 1986 Nov-Dec; 56(6):467-73.AI

Abstract

Enalapril (E) was used to treat 16 patients with pulmonary arterial hypertension, 6 primary and 10 secondary, 5 of the latter with congenital heart disease and 5 with chronic obstructive pulmonary disease. The average dose of E was 20 mg/day. All patients underwent pre and post-treatment cardiac catheterization with determination of pressures at: right atrial (RA), main pulmonary artery (MPA), pulmonary capillary wedge pressure (VCP) and systemic arterial (SA). Resistances forces were also measured as; total pulmonary (TPR), pulmonary arteriolar (PAR) and total systemic (TSR) as well as cardiac output (CO), and echo and electrocardiograms, chest x ray, stress test and respiratory function test. The functional class (NYHA) improved in all (p less than 0.001). The initial mean pressures were: RA 12.24 +/- 4.35; MPA 73.81 +/- 25.16; VCP 12 +/- 2.73 and SA 89 +/- 14; TPR 1477 +/- 761; PAR 1243 +/- 730 and TSR 1684 +/- 505.5; CO 4.5 +/- 1.29. The final values were: RA 9.66 +/- 2.46 (p less than 0.001); MPA 63.26 +/- 24.45 (p less than 0.001); VCP 11.33 +/- 2.38 (p = NS); SA 81 +/- 10 (p less than 0.001); TPR 1009.5 +/- 536.7 (p less than 0.001); PAR 829 +/- 511.5 (p less than 0.001); TSR 1309.6 +/- 296.3 (p less than 0.001); CO 5.2 +/- 1.44 (p less than 0.001). The average of minutes on treadmill was initially 8.2 +/- 2.45 and final 12.46 +/- 3.0 (p less than 0.001). It is concluded that enalapril is a useful drug in the treatment of pulmonary arterial hypertension of any etiology.

Authors

Escudero J
No affiliation info available
Navarro J
No affiliation info available
Padua A
No affiliation info available
Betancourt L
No affiliation info available
Nava G
No affiliation info available

MeSH

AdultAngiotensin-Converting Enzyme InhibitorsCardiac CatheterizationDrug EvaluationEnalaprilFemaleHeart Defects, CongenitalHemodynamicsHumansHypertension, PulmonaryLung Diseases, ObstructiveMaleMiddle AgedRespiratory Function Tests

Pub Type(s)

English Abstract
Journal Article

Language

spa

PubMed ID

3032121

Citation

Escudero, J, et al. "[Use of Enalapril, an Angiotensin-converting Enzyme Inhibitor, in Pulmonary Artery Hypertension]." Archivos Del Instituto De Cardiologia De Mexico, vol. 56, no. 6, 1986, pp. 467-73.
Escudero J, Navarro J, Padua A, et al. [Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension]. Arch Inst Cardiol Mex. 1986;56(6):467-73.
Escudero, J., Navarro, J., Padua, A., Betancourt, L., & Nava, G. (1986). [Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension]. Archivos Del Instituto De Cardiologia De Mexico, 56(6), 467-73.
Escudero J, et al. [Use of Enalapril, an Angiotensin-converting Enzyme Inhibitor, in Pulmonary Artery Hypertension]. Arch Inst Cardiol Mex. 1986 Nov-Dec;56(6):467-73. PubMed PMID: 3032121.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension]. AU - Escudero,J, AU - Navarro,J, AU - Padua,A, AU - Betancourt,L, AU - Nava,G, PY - 1986/11/1/pubmed PY - 1986/11/1/medline PY - 1986/11/1/entrez SP - 467 EP - 73 JF - Archivos del Instituto de Cardiologia de Mexico JO - Arch Inst Cardiol Mex VL - 56 IS - 6 N2 - Enalapril (E) was used to treat 16 patients with pulmonary arterial hypertension, 6 primary and 10 secondary, 5 of the latter with congenital heart disease and 5 with chronic obstructive pulmonary disease. The average dose of E was 20 mg/day. All patients underwent pre and post-treatment cardiac catheterization with determination of pressures at: right atrial (RA), main pulmonary artery (MPA), pulmonary capillary wedge pressure (VCP) and systemic arterial (SA). Resistances forces were also measured as; total pulmonary (TPR), pulmonary arteriolar (PAR) and total systemic (TSR) as well as cardiac output (CO), and echo and electrocardiograms, chest x ray, stress test and respiratory function test. The functional class (NYHA) improved in all (p less than 0.001). The initial mean pressures were: RA 12.24 +/- 4.35; MPA 73.81 +/- 25.16; VCP 12 +/- 2.73 and SA 89 +/- 14; TPR 1477 +/- 761; PAR 1243 +/- 730 and TSR 1684 +/- 505.5; CO 4.5 +/- 1.29. The final values were: RA 9.66 +/- 2.46 (p less than 0.001); MPA 63.26 +/- 24.45 (p less than 0.001); VCP 11.33 +/- 2.38 (p = NS); SA 81 +/- 10 (p less than 0.001); TPR 1009.5 +/- 536.7 (p less than 0.001); PAR 829 +/- 511.5 (p less than 0.001); TSR 1309.6 +/- 296.3 (p less than 0.001); CO 5.2 +/- 1.44 (p less than 0.001). The average of minutes on treadmill was initially 8.2 +/- 2.45 and final 12.46 +/- 3.0 (p less than 0.001). It is concluded that enalapril is a useful drug in the treatment of pulmonary arterial hypertension of any etiology. SN - 0020-3785 UR - https://www.unboundmedicine.com/medline/citation/3032121/[Use_of_enalapril_an_angiotensin_converting_enzyme_inhibitor_in_pulmonary_artery_hypertension]_ L2 - https://www.diseaseinfosearch.org/result/6088 DB - PRIME DP - Unbound Medicine ER -